Quantbot Technologies LP Invests $5.02 Million in Teleflex Incorporated (NYSE:TFX)

Quantbot Technologies LP acquired a new position in shares of Teleflex Incorporated (NYSE:TFX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 28,210 shares of the medical technology company’s stock, valued at approximately $5,021,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Goodman Financial Corp acquired a new position in Teleflex in the fourth quarter valued at approximately $13,378,000. Semanteon Capital Management LP purchased a new position in Teleflex in the fourth quarter valued at approximately $778,000. Blueshift Asset Management LLC purchased a new position in Teleflex in the fourth quarter valued at approximately $362,000. iA Global Asset Management Inc. purchased a new position in Teleflex in the fourth quarter valued at approximately $258,000. Finally, Magnetar Financial LLC increased its stake in Teleflex by 105.2% in the fourth quarter. Magnetar Financial LLC now owns 421,340 shares of the medical technology company’s stock valued at $74,990,000 after purchasing an additional 215,961 shares during the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TFX shares. Needham & Company LLC reissued a “hold” rating on shares of Teleflex in a report on Wednesday. Royal Bank of Canada downgraded Teleflex from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $220.00 to $155.00 in a report on Friday, February 28th. Morgan Stanley decreased their price objective on Teleflex from $275.00 to $191.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. Bank of America downgraded Teleflex from a “neutral” rating to an “underperform” rating and decreased their price objective for the company from $235.00 to $140.00 in a report on Tuesday, March 4th. Finally, Truist Financial decreased their price objective on Teleflex from $200.00 to $149.00 and set a “hold” rating for the company in a report on Monday, March 3rd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $182.63.

Teleflex Price Performance

Teleflex stock opened at $137.79 on Friday. Teleflex Incorporated has a one year low of $128.55 and a one year high of $249.90. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. The business has a fifty day moving average of $166.99 and a two-hundred day moving average of $197.99. The company has a market cap of $6.39 billion, a P/E ratio of 27.39, a price-to-earnings-growth ratio of 1.73 and a beta of 1.21.

Teleflex (NYSE:TFX) last released its earnings results on Thursday, February 27th. The medical technology company reported $3.89 EPS for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The company had revenue of $795.40 million during the quarter, compared to the consensus estimate of $813.24 million. As a group, analysts predict that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 17th. Stockholders of record on Friday, March 7th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date is Friday, March 7th. Teleflex’s dividend payout ratio is currently 95.77%.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.